

# **EURL-SRM - Analytical Observations Report**

concerning the following...

Compound(s):

Boscalid metabolite M510F01,

Fenpropidin metabolite CGA289267 Isoxaflutole metabolite RPA202248 Isoxaflutole metabolite RPA203328

Spiroxaminecarboxylic acid

Fenpropimorph carboxylic acid BF-421-2 Trifloxystrobin metabolite CGA 321113 Dimoxystrobin metabolite 505M09

Commodities: muscle, liver, kidney, milk

Extraction Method(s): QuEChERS (citrate) with C18 clean-up

Instrumental analysis: LC-MS/MS

# Analysis of various relevant pesticide metabolites of in products of animal origin by the QuEChERS Method using LC-MS/MS

Version 1 (last update: 25.04.2018)

## **Background information / Initial Observations:**

Numerous pesticides are being annually re-evaluated according to Article 12 of Regulation 396/2005/EC. Where indicated, new MRLs and sometimes also new residue definitions are set. Within this framework the EURLs are involved in assessing the analytical amenability of residue definitions proposed for enforcement purposes and in elaborating possible consensus LOQs for the main commodity classes, which are considered when setting residue limits for products where no residues are expected (MRL\*s). Within this context, the EURL-SRM mainly focuses on pesticides and relevant metabolites, which are known to pose problems in analysis and are thus considered "difficult" or non-amenable to multiresidue methods. It is first tested whether the analytes or residue definitions can be analyzed by introducing, preferably simple, modifications to traditional multiresidue methods (MRMs, mainly QuEChERS), and if not new methods are developed. Modifications of MRMs may entail various measures to prevent degradation or improve extractability of residues (e.g. adjustment of pH, addition of substances and adjustment of extraction temperature and time), cleavage reactions to release conjugates, special measurement conditions and other. In case of highly polar pesticides, that do not readily partition into the acetonitrile phase of the QuEChERS method, the QuPPe method, which does not involve a partitioning step, or variations thereof are tested.

The present analytical observations report deals with a number of metabolites that are relevant to products of animal origin and that, for various reasons, are expected to pose difficulties in analysis.



The following metabolites were selected for this study:

- Boscalid metabolite M510F01 (residue definition entails conjugates),
- Fenpropidin metabolite CGA289267 (amphoteric: acidic and basic),
- Fenpropimorph metabolite BF421-2 (amphoteric: acidic and basic),
- Spiroxamine carboxylic acid (amphoteric: acidic and basic),
- Isoxaflutole metabolite RPA 203328 (weakly acidic),
- Isoxaflutole metabolite RPA 203348 (acidic and highly polar),
- Trifloxystrobin metabolite CGA 321113 (acidic),
- Dimoxystrobin metabolite 505M09 (acidic)

In most cases these substances had to be ordered from applicants, as they were not yet available in the analytical standards market when the analyses started. Priority was given to metabolites associated with compounds being re-evaluated according to Article 12 of Reg 396/2005/EC, or that were included at some point within the scope of EU coordinated monitoring program or within the scope of the DG-SANTE Working Document, which gives guidance to the Member States in designing their own National monitoring programs.

#### **Compound details:**

Boscalid metabolite M5	10F01	
Parameter	Value	
Molecular Mass	359.21 g/mol	
Exact mass	358.027583 Da	N
CAS	661463-87-2	CI
IUPAC name	2-Chloro-N-(4'-chloro-5-hydroxybiphenyl-2-yl)nicotinamide	o=<
pKa (calculated)	ACD/Labs: $pK_{a1} = 0.9$ ; $pK_{a2} = 9.4$ ; $pK_{a3} = 11.1$ Chemicalize: $pK_{a1} = -0.1$ @ pyridine-N moiety (weakly basic) $pK_{a2} = 9.3$ @ phenol moiety (weakly acidic), $pK_{a3} = 14.6$ @ amide-N moiety (weakly acidic) Virtually non-ionized in the pH-range from 2-7	NH CI
LogD (calculated)	ACD/Labs: 3.9 (pH 5.5)  Chemicalize: Virtually non-ionized and with constant polarity in the pH range of 2-8 (highest logD =4.62 non-ionic form),	НО
Residue definition EU Reg. (EU) 2016/156	Boscalid (F) (R) (A) (R) = The residue definition differs for the following combinations pesti code 1000000 except 1040000, 1011010, 1011020, 1011050, 101201 1013010, 1013020, 1013050, 1014010, 1014020, 1014050, 1015010, 1016010, 1016020, 1017010, 1017020, 1017050, 1020000, 1030000: hydroxy metabolite 2-chloro-N-(4'-chloro-5-hydroxybiphenyl-2-yl)nicoti ed) expressed as boscalid	0, 1012020, 1012050, 1015020, 1015050, Sum of boscalid and its
	This means that the M510F01 (the hydroxyl-metabolite of boscalid) is <b>kidney</b> of swine, bovine, goat, sheep, equine, poultry and other <u>farme</u> as for other edible offal of poultry.	ed terrestrial animals as well
Boscalid is approved in	AT, BE, BG, CY, CZ, DE, DK, EE, EL, ES, FI, FR, HR, HU, IE, IT, LT, RO, SE, SI, SK, UK	LU, LV, MI, NL, PL, PI,
ADI / ARfD	0.04 mg/kg bw per day / Not applicable (08/44/EC)	

Fenpropidin metabolite	CGA289267	
Parameter	Value	
Molecular Mass	303.4 g/mol	_
Exact mass	303.279829 Da	_
CAS	-	_
IUPAC name	2-methyl-2-{4-[2-(piperidin-1- ylmethyl)propyl]phenyl}propanoic acid	- H <sub>3</sub> C
pKa (calculated)	ACD/Labs: $pK_{a1} = 4.4$ ; $pK_{a2} = 9.7$ Chemicalize: $pK_{a1} = 4.4$ @ carboxy-moiety (intermediately acidic); $pK_{a2} = 10.0$ @ piperidine-N (strongly basic); predominantly cationic at $pH<4.5$ ; predominantly anionic at $pH>10$ ; predominantly doubly charged at $pH=4.5-10$	HO CH <sub>3</sub> CH <sub>3</sub>
LogD (calculated)	ACD/Labs: 1.6 (pH 5.5) Chemicalize: Lowest polarity in the range between pH 5 and 9 (highest logD = 1.87)	
Residue definition EU Reg. (EU) 2014/61	Fenpropidin (sum of fenpropidin and its salts, expr (R) = The residue definition differs for the following fenpropidin-code 1000000 except 1040000: sum of din-1-yl-propyl)-phenyl]propionic acid, and their sa This means that the CGA289267 (the carboxy-me modities of animal origin except apicultural pro-	g combinations pesticide-code number: of fenpropidin, 2-methyl-2-[4-(2-methyl-3- piperi- lts, expressed as fenpropidin tabolite of fenpropidin) is relevant for all com-
Fenpropidin is approved in	AT, BE, CZ, DE, EE, EL, ES, FI, FR, HR, HU, IE,	IT, LT, LU, LV, NL, PL, PT, RO, SE, SI, SK, UK
ADI / ARfD	0.02 mg/kg bw per day / 0.02 mg/kg bw (Dir 08/66	5)

Isoxaflutole metabolite	RPA202248
Parameter	Value
Molecular Mass	359.3 g/mol
Exact mass	359.043912 Da
CAS	143701-75-1
IUPAC name	3-cyclopropyl-2-[2-methanesulfonyl-4-(trifluoromethyl)benzoyl]-3- oxopropanenitrile
pKa (calculated)	ACD/Labs: $pK_{a1} = 1.1$ Chemicalize: $pK_{a1} = 5.4$ @ CH moiety in alpha position to CO, CO and CN (weakly acidic)
LogD (calculated)	ACD/Labs: logD -0.3 (pH 7) Chemicalize: Lowest polarity when pH <4 (highest logP= 2.03), highest polarity when pH >9 (lowest logP= 0.11); logP 1.92 (pH 5); 1.5 (pH 6)
Residue definition EU Reg. (EU) 2015/845	Isoxaflutole (sum of isoxaflutole and its diketonitrile-metabolite, expressed as isoxaflutole) Footnote: RPA 202248 is 2-cyano-3-cyclopropyl-1-(2-methylsulfonyl-4-trifluoromethylphenyl) propane-1,3-dione. RPA 203328 is 2-methanesulfonyl-4-trifluoromethylbenzoic acid. This means that the RPA202248 (the diketonitrile-metabolite of isoxaflutole) is relevant for all commodities of plant and animal origin. The mentioning of RPA 203328 in the footnote must be
la sueflutale la annua d	an error.
Isoxaflutole is approved in	AT, BE, BG, CZ, DE, EL, ES, FR, HR, HU, IE, IT, LU, NL, PL, PT, RO, SI, SK, UK
ADI / ARfD	0.02 mg/kg bw per day / ARfD not applicable



Isoxaflutole metabolite	RPA203328	
Parameter	Value	
Molecular Mass	268.21 g/mol	
Exact mass	268.001713 Da	ОН
CAS	142994-06-7	
IUPAC name	2-methanesulfonyl-4-(trifluoromethyl)benzoic acid	H <sub>3</sub> C F
pKa (calculated)	ACD/Labs: $pK_{a1} = 2.0$ ; No base $pK_a$ Chemicalize: $pK_{a1} = 2.3$ (strongly acidic, carboxy moiety)	S
LogD (calculated)	ACD/Labs: -1.2 (pH 7) Chemicalize: logD 1.16 (pH2); 0.54 (pH3), -0.38 (pH 4), -1.3 (pH 5), -2.0 (pH 6).	Ö F
Residue definition EU Reg. (EU) 2015/845	Not regulated. The mentioning of RPA 203328 in the footnote must be a	n error (see above)
Isoxaflutole is approved in	AT, BE, BG, CZ, DE, EL, ES, FR, HR, HU, IE, IT, LU, NL, PL, PT, RO	, SI, SK, UK
ADI / ARfD	0.02 mg/kg bw per day / ARfD not applicable	

Spiroxamine carboxyli	c acid	
Parameter	Value	
Molecular Mass	327.46 g/mol	
Exact mass	327.240959 Da	
CAS	156042-38-5	
IUPAC name	2-(2-{[ethyl(propyl)amino]methyl}-1,4-dioxaspiro[4.5]decan-8-yl)-2-methylpropanoic acid	,O ,CH <sub>3</sub>
pKa (calculated)	ACD/Labs: $pK_{a1} = 4.8$ ; $pK_{a2} = 8.8$ Chemicalize: $pK_{a1} = 4.1$ @ carboxylic acid moiety (intermediately acidic); $pK_{a2} = 9.3$ @ quarternary amine (intermediately basic); predominantly cationic at pH<4; predominantly anionic at pH >9; predominantly doubly charged at pH 4-9	H CH <sub>3</sub>
LogD (calculated)	ACD/Labs: 0.7 (pH 7) Chemicalize: Lowest polarity in the range between pH 5 and 8.5 (highest logD = 0.84)	
Residue definition EU Reg. (EU) 2016/452	Spiroxamine (sum of isomers) (A) (R)  (A) = The EU reference labs identified the reference standard olite M06 as commercially not available. When re-viewing the account the commercial availability of the reference standard March 2017, or, if that reference standard is not commercially of it.  (R) = The residue definition differs for the following combining Spiroxamine — code 1000000 except 1040000: Spiroxamine pressed as spiroxamine (sum of isomers)  This means that the spiroxamine carboxylic acid is relevant except apicultural products	he MRL, the Commission will take into rd referred to in the first sentence by 30 ally available by that date, the unavailabilations pesticide-code number: ne carboxylic acid metabolite M06, ex-
Spiroxamine is approved in	AT, BE, BG, CY, CZ, DE, DK, EE, EL, ES, FR, HR, HU, IE	, IT, LT, LU, LV, PL, PT, RO, SI, SK, UK
ADI / ARfD	0.025 mg/kg bw per day / 0.1 mg/kg bw	



Fenpropimorph carbo	kylic acid (BF-421-2)	
Parameter	Value	
Molecular Mass	333.47 g/mol	
Exact mass	333.230394 Da HO————————————————————————————————————	
CAS	121098-45-1 H <sub>3</sub> C	
IUPAC name	2-(4-{3-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-methylpropyl}phenyl)- 2-methylpropanoic acid	
pKa (calculated)	ACD/Labs: $pK_{a1} = 4.4$ ; $pK_{a2} = 7.3$ Chemicalize: $pK_{a1} = 4.4$ @ carboxylic acid moiety (intermediately acidic); $pK_{a2} = 8.5$ @morpholine-N (intermediately basic); predominantly cationic at $pH < 4.5$ ; predominantly anionic at $pH > 8.5$ ; predominantly doubly charged at $pH = 4.5$ .	
LogD (calculated)	ACD/Labs:1.3 (pH 7)  Chemicalize: Lowest polarity in the range between pH 5 and 8  (highest logD = 1.65)	
Residue definition EU Reg. (EU) 2017/170	Fenpropimorph (sum of isomers) (F) (R)  R) = The residue definition differs for the following combinations pesticide-code number: Fenpropimorph - code 1000000: Fenpropimorph carboxylic acid (BF 421-2) expressed as fenpropimorph This means that fenpropimorph carboxylic acid is relevant for all commodities of animal origin including apicultural products	
Fenpropimorph is approved in	AT, BE, BG, CZ, DE, EE, EL, ES, FR, HR, HU, IE, IT, LT, LU, LV, NL, PL, RO, SE, SI, SK, UK	
ADI / ARfD	0.003 mg/kg bw per day / 0.03 mg/kg bw	

Trifloxystrobin metabo	lite CGA 321113	
Parameter	Value	
Molecular Mass	394.34 g/mol	
Exact mass	394.114042 Da	-
CAS	252913-85-2	- CH
IUPAC name	(2E)-2-(methoxyimino)-2-[2-({[(E)-{1-[3-trifluoromethyl) phenyl]ethylidene}amino]oxy}methyl)phenyl]acetic acid	F V O
pKa (calculated)	ACD/Labs: $pK_{a1} = 2.8$ ; No base $pK_a$ Chemicalize: $pK_{a1} = 3.2$ @carboxylic acid moiety (strongly acidic); $pK_{a2} = 2.25$ @imino-moiety (weakly basic); $pK_{a3} = -0.45$ @methoxy-imino-moiety (very weakly basic);	H <sub>3</sub> C O N OH
LogD (calculated)	ACD/Labs: 0.6 (pH 7) Chemicalize: lowest polarity (highest logD = 4.2) at pH 2.8; pH4 logD=3.5; pH5 logD=2.6; pH5 logD=1.7	_
Residue definition EU Reg. (EU) 2017/626	Trifloxystrobin (A) (F) (R)  (A) = The EU reference labs identified the reference standard available. When re-viewing the MRL, the Commission will take of the reference standard referred to in the first sentence by 23 is not commercially available by that date, the unavailability of (F) = Fat soluble  (R) = The residue definition differs for the following combination Trifloxystrobin- code 1000000 except 1040000: the sum of trifl methoxyimino- {2-[1-(3-trifluoromethyl-phenyl)-ethylideneamin 321113)	e into account the commercial availability 3 July 2016, or, if that reference standard it. ons pesticide-code number: oxystrobin and its metabolite (E, E)-
Tritosulfuron is approved in	AT, BE, BG, CY, CZ, DE, EL, ES, FI, FR, HR, HU, IE, IT, LT, I	LU, MT, NL, PL, PT, RO, SE, SI, SK, UK
ADI / ARfD	0.1 mg/kg bw per day / ARfD not applicable	

Dimoxystrobin metabo	olite 505M09	
Parameter	Value	
Molecular Mass	356.37 g/mol	
Exact mass	356.137222 Da	_
CAS	1418095-11-0	0
IUPAC name	3-({2-[(E)-(methoxyimino)(methylcarbamoyl) methyl]phenyl}methoxy)-4-methylbenzoic acid	НО
pKa (calculated)	ACD/Labs: $pK_{a1} = -1.7$ ; $pK_{a2} = 4.2$ ; $pK_{a3} = 11.3$ Chemicalize: $pK_{a1} = 4.06$ @carboxylic acid moiety (intermediately acidic); $pK_{a2} = 14.66$ @methylamide moiety (very weakly basic); $pK_{a3} = 0.62$ @methoxy- imino-moiety (very weakly basic); ACD/Labs: 1.3 (pH 7) Chemicalize: lowest polarity (highest logD ~3) at pH 1.5-3	CH <sub>3</sub> CH <sub>3</sub>
1-095	logD 2.8 (pH 4), 2.0 (pH 5), 1.1 (pH 6)  Dimoxystrobin (R) (A)	
Residue definition EU Reg. (EU) 2015/1040	(A) = The EU reference labs identified the reference st able. When re-viewing the MRL, the Commission will the reference standard referred to in the first sentence is not commercially available by that date, the unavailate (R) = The residue definition differs for the following corn Dimoxystrobin — code 1000000 except 1040000: 505I Metabolite 505M09 = 3-({2-[(1E)-N-methoxy-2-(methylemethylbenzoic acid	ake into account the commercial availability of by 1 July 2016, or, if that reference standard ability of it.  mbinations pesticide-code number:  M09, expressed as dimoxystrobin.
Dimoxystrobin is approved in	AT, BE, BG, CZ, DE, EE, FR, HR, HU, LT, LU, L	V, PL, RO, SK, UK
ADI / ARfD	0.004 mg/kg bw per day / 0.004 mg/kg bw	



#### **Consumables:**

## **Analytical Standards:**

Table 1: Sources of analytical standards (exemplary)

Substance	Purity	CAS	Source	Order number
Boscalid met. M510F01	95.7%	661463-87-2	BASF (friendly donation) <sup>1</sup>	-
	on request	•	HPC Standards GmbH	681008
	>=95	•	Sigma-Aldrich Chemie GmbH	28001-10MG
Fenpropidin met. CGA289267	98%	?	Syngenta (friendly donation)	=
Isoxaflutole met. RPA202248	99.5%	143701-75-1	Bayer CropScience (friendly donation)	-
	on request		HPC Standards GmbH	679125
	on request		Toronto Research Chemicals	R700915
Isoxaflutole met. RPA203328	95%	142994-06-7	Fluoro Chem Ltd.	-
	on request		HPC Standards GmbH	679380
	on request		Toronto Research Chemicals	M328135
	on request		Sigma-Aldrich Chemie GmbH	MAT370172678- 1G/074529-1G
Spiroxamine carboxylic acid	71.1%	156042-38-5	Bayer CropScience (friendly donation)	=
Fenpropimorph carboxylic acid	99.8%	121098-45-1	BASF	=
(BF-421-2)	on request		HPC Standards GmbH	681497
	on request		Toronto Research Chemicals	F249510
	on request		CHEMOS GmbH & Co. KG	-
	on request	•	BOC Sciences	-
Trifloxystrobin met. CGA 321113	99.9%	252913-85-2	Sigma-Aldrich	34518-10MG
	99.9%		CHEMOS GmbH & Co. KG	WS252913852.5ml
	on request	=	BOC Sciences	=
Dimoxystrobin metabolite 505M09	96.8%	1418095-11-0	Sigma-Aldrich	93127-10MG
	on request	-	HPC Standards GmbH	681007
Propyzamid D3	99%	-	CDN Isotopes	D-6431
1,3-bis(4-nitrophenyl)urea (BNPU)	99.5%	330-95-0	Sigma-Aldrich	-

All other materials and chemicals used as listed in EN 15662

<sup>1</sup> used for experiments



#### **Measurement conditions**

Measurement was conducted by LC-MS/MS in the ESI-positive and ESI-negative mode depending on the compound. Details are given in *Table 2*, *Table 3* and *Table 4*.

Table 2: LC-instrumentation details

LC	WATERS Acquity UPLC					
MS/MS	SCIEX API 4000 Q-Trap, run in ESI positive mode or in ESI negative mode					
Column	Acquity BEH C18, 2.1x100 mm	, 1.7 μm				
Pre-column	Acquity BEH C18, 2.1x5 mm, 1	.7 μm				
Mobile Phase	ESI positive mode					
	A: 5 mmol NH <sub>4</sub> formate in purific	ed water (5% methanol)				
	B: 5 mmol NH <sub>4</sub> formate in metha	anol				
	ESI negative mode					
	A: 0.01% acetic acid in purified	water (5% acetonitrile)				
	B: 0.01% acetic acid in acetonit	trile				
Gradient	Time (min)	Mobile Phase A (%)	Mobile Phase B (%)			
	0	95	5			
	0.5	60	40			
	4	10	90			
	8	10	90			
	8.1	95	5			
Equilibration Time	5 min					
Run Time	13 min					
Flow	0.4 mL min <sup>-1</sup>					
Injection volume	2 μL, partial loop with needle ov	verfill				
Column temperature	40°C					

Table 3: MS/MS details (ESI-pos. mode using Sciex API 4000 QTrap<sup>2</sup>):

Compound	Intensity ranking	Q 1	Q 3	DP	CE	CXP
	1	304.2	107.1	36	69	4
Fenpropidin met. CGA289267	2	304.2	117.1	36	71	6
CGA209201	3	304.2	105.0	36	69	2
Spiroxamine car-	1	328.2	144.1	71	31	8
boxylic acid	2	328.2	100.0	71	51	4
Fenpropimorph	1	334.2	107.0	101	55	4
carboxylic acid	2	334.2	105.1	101	59	4
(BF-421-2)	3	334.2	91.1	101	81	4
	1	395.0	186.0	56	25	10
Trifloxystrobin met.	2	395.0	145.0	56	61	8
CGA 321113	3	395.0	115.9	56	47	6
	4	395.0	89.2	56	95	4
Dimensional in most	1	357.0	116.1	66	35	6
Dimoxystrobin met. 505M09 <sup>3</sup>	2	357.0	205.1	66	19	10
	3	357.0	250.2	66	21	2
Propyzamid D3	-	259.2	193.0	41	21	10

<sup>&</sup>lt;sup>2</sup> An older generation instrument API 4000 QTrap is used for validation studies in order to generate LOQs that can be monitored by the majority of laboratories. When using an **API 5500** instrument increase DP values by 20 in absolute terms.

<sup>&</sup>lt;sup>3</sup> **Dimoxystrobin met. 505M09** can also be measured in ESI positive mode, at a slightly better sensitivity than in the ESI negative mode, but within this study it was measured at the ESI negative mode

Table 4: MS/MS details (ESI-neg. mode using Sciex API 4000 QTrap<sup>4</sup>):

Compound	Intensity ranking	Q 1	Q 3	DP	CE	СХР
D	1	357.0	244.0	-75	-28	-1
Boscalid met. M510F01	2	359.0	246.0	-75	-28	-1
WISTOTOT	3	359.0	244.0	-75	-26	-1
	1	358.0	78.9	-60	-30	-1
Isoxaflutole met.	2	358.0	64.0	-60	-78	-1
RPA202248	3	358.0	107.9	-60	-46	-5
	4	358.0	277.9	-60	-20	-7
	1	267.0	222.8	-45	-14	-11
Isoxaflutole met.	2	267.0	158.9	-45	-26	-7
RPA203328	3	267.0	64.1	-45	-70	-1
	4	267.0	79.1	-45	-46	-1
Dimensional in most	1	355.0	105.9	-75	-38	-3
Dimoxystrobin met. 505M09	2	355.0	266.1	-75	-20	-1
30314103	3	355.0	149.9	-75	-26	-1
	4	355.0	222.0	-75	-26	-9
1,3-bis(4- nitrophenyl)urea (BNPU)	-	301.1	136.9	-45	-16	-7
Propyzamid D3	•	257.0	231.0	-70	-20	-1

### **Experiments conducted and observations:**

The validation experiments were based on the QuEChERS procedure (EN-15662<sup>5</sup>). The main focus was on muscle, liver, kidney and on full fat cow's milk. In all cases recovery experiments were conducted at two spiking levels (0.01 mg/kg and 0.05 mg/kg). The results of the validation experiments are shown in *Table 5* and

<sup>&</sup>lt;sup>4</sup> An older generation instrument API 4000 QTrap is used for validation studies in order to generate LOQs that can be monitored by the majority of laboratories. When using an **API 5500** instrument increase DP values by 20 in absolute terms.

<sup>&</sup>lt;sup>5</sup> Detailed instructions on the QuEChERS method are given in the CEN method EN 15662 (citrate buffered), see also brief description under



Table 6. Two mass transitions were evaluated for each compound.

Fenpropidin metab. CGA 289267, spiroxamine carboxylic acid, fenpropimorph carboxylic acid (BF-421-2) and trifloxystrobin metab. CGA 321113 were analyzed in the **ESI-positive** mode using propyzamid-D3 as internal standard. At the 0.05 mg/kg spiking level mean recovery rates were between 80-120% (the range within which no correction for recovery is required) and RSDs ≤ 12 % for all compounds and both mass transitions. At the 0.01 mg/kg recovery rates were outside the 80-120% range for one mass transition of CGA 321113 (rec. 79%) and one mass transition of CGA 289267 (rec. 124%). RSDs were ≤ 15 % in all cases except for one mass transition of CGA 321113 (RSD 22%).

Table 5: Recovery rates from various AO commodities using QuEChERS EN-15662 with C-18 cleanup (without PSA),, n=5 (ESI-pos. mode using Sciex API 4000 QTrap):

Matrix	Anal. Portion	Water added	Spiking level	Compound	Mass Transition [m/z]	Mean Recov. (n=5)	RSD %		
				Fonoropidio motob CCA 200267	304/107	93%	5		
				Fenpropidin metab. CGA 289267	304/117	Ansition (z)         Recov. (n=5)         RS (m=5)           4/107         93%         5           4/117         97%         9           8/144         102%         6           8/100         96%         2           4/107         98%         11           4/105         88%         8           5/186         85%         10           5/145         79%         9           4/107         100%         2           4/107         100%         5           8/144         102%         2           4/105         94%         3           5/186         94%         2           5/145         93%         3           4/107         104%         8           4/107         104%         8           4/107         104%         8           4/107         93%         3           4/107         93%         12           4/105         94%         10           5/186         87%         9           5/186         87%         9           5/186         87%         9           5/186 <t< td=""><td>9</td></t<>	9		
				Spiroxamine carboxylic acid	328/144		6		
Muscle	5 g	5 mL	0.01 mg/kg	Spiroxamine carboxylic acid	328/100	96%	2		
(bovine)			3. 3.	Fenpropimorph carboxylic acid (BF-421-2)	334/107	98%	11		
				T emproprintorphi carboxylic acid (Bi -421-2)	334/105	88%	8		
				Trifloxystrobin metab. CGA 321113	395/186	85%	10		
				Tilloxystrobii metab. CGA 321113	395/145	79%	9 6 2 11 8 10 9 2 5 2 2 5 3 2 3 8 11 8		
				Fenpropidin metab. CGA289267	304/107	100%	2		
				Tempropidin metab. OCA209207	304/117	100%	5		
				Spiroxamine carboxylic acid	328/144	102%	2		
Muscle	5 g	5 mL	0.05 mg/kg	Opiroxamine darboxyne deld	328/100	105%	2		
(swine)				Fenpropimorph carboxylic acid (BF-421-2)	334/107	94%	5		
				3	334/105	100% 5 102% 2 105% 2 94% 5 94% 3 94% 2 93% 3 104% 8	3		
				Trifloxystrobin metab. CGA 321113	395/186	94% 5 94% 3 94% 2 93% 3			
				Timoxyotrobii Inclas. Ge/(G21116	395/145	93%	3		
				Fenpropidin metab. CGA 289267	304/107	104%	8		
				Temproprain metab. Gen 200207	304/117	124%	11		
				Spiroxamine carboxylic acid	328/144	111%	8		
Milk	10 g	_	0.01 mg/kg	Opiroxamino darboxyno dold	328/100	111%	9		
(cow's)	10 9		o.o.i mg/ng	Fenpropimorph carboxylic acid (BF-421-2)	334/107	93%	12		
				T disproprime pri dale dale (El 1212)	334/105		10		
				Trifloxystrobin metab. CGA 321113	395/186	87%	9		
					395/145		13		
Milk				Fenpropidin metab. CGA 289267	304/107	111%	1		
(cow's)	10 g	-	0.05 mg/kg		304/117	94% 5 94% 3 94% 2 93% 3 104% 8 124% 11 111% 8 111% 9 93% 12 94% 10 87% 9 95% 13 111% 1			
,				Spiroxamine carboxylic acid	328/144	104%	3		



Matrix	Anal. Portion	Water added	Spiking level	Compound	Mass Transition [m/z]	Mean Recov. (n=5)	RSD %		
					328/100	107%	4		
			F : 1   1   1   1   1   1   1   1   1   1	334/107	98%	2			
				Fenpropimorph carboxylic acid (BF-421-2)	334/105	101%	2		
				Trifloxystrobin metab. CGA 321113	395/186	100%	2		
				Tillioxystrobiii filetab. CGA 321113	395/145	99%	3		
				Fenpropidin metab. CGA 289267	304/107	105%	5		
				renpropidin metab. CGA 269207	304/117	107%	13		
				Spiroxamine carboxylic acid	328/144	108%	6		
Liver	5 g	5 mL	0.01 mg/kg	Spiroxamine carboxylic acid	328/100	113%	3		
(bovine)	- 3		are viniging	Fenpropimorph carboxylic acid (BF-421-2)	334/107	98%	10		
					334/105	8			
				Trifloxystrobin metab. CGA 321113	395/186	395/186 90%			
				TillioxystrobiiTilletab. CGA 321113	395/145	89%	5		
				Fenpropidin metab. CGA 289267	304/107	99%	6		
				renpropidin metab. CGA 269207	304/117	98%	6		
			0.05 mg/kg	Spiroxamine carboxylic acid	328/144	99%	7		
Liver	5 g	5 mL			328/100	98%	6		
(bovine)				Fenpropimorph carboxylic acid (BF-421-2)	334/107	89%	7		
				T emproprimorphi carboxylic dola (Bi 4212)	334/105	91%	8		
				Trifloxystrobin metab. CGA 321113	395/186	334/107 89% 7 334/105 91% 8 395/186 90% 7 395/145 87% 1			
				Timoxystrobii metab. OOA 321113	395/145	87%	12		
				Fenpropidin metab. CGA 289267	304/107	99%	98%         2           101%         2           100%         2           99%         3           105%         5           107%         13           108%         6           113%         3           98%         10           87%         8           90%         7           89%         5           99%         6           98%         6           99%         7           98%         6           89%         7           91%         8           90%         7           87%         12		
				Tempropidin metab. Gov. 200207	letab. CGA 289267				
				Spiroxamine carboxylic acid	328/144	99%	10		
Kidney mix	5 g	5 mL	0.01 mg/kg	opiroxamino darboxyno dold	328/100	020/			
(Swine+Bovine)				Fenpropimorph carboxylic acid (BF-421-2)	334/107	101%	15		
				T onproprinterpri carboxynic acia (Br. 1212)	334/105	102%	9		
				Trifloxystrobin metab. CGA 321113	395/186	106%			
				Timoxyonobii motab. CortoZTTTO	395/145	94%	13		
				Fenpropidin metab. CGA 289267	304/107	(n=5)         %           107%         4           98%         2           101%         2           100%         2           99%         3           105%         5           107%         13           108%         6           113%         3           98%         10           87%         8           90%         7           89%         6           99%         6           98%         6           99%         7           98%         6           89%         7           91%         8           90%         7           87%         12           99%         4           110%         13           99%         10           102%         6           101%         15           102%         9           106%         22           94%         13           10%         5           98%         12           103%         6           110%         5	9		
				- 5.1p. opidii i i i i i i i i i i i i i i i i i	304/117	98%	12		
				Spiroxamine carboxylic acid	328/144		6		
Kidney mix	5 g	5 mL	0.05 mg/kg	Spirozamino sarbozyno dola	328/100	110%	5		
(Swine+Bovine)				Fenpropimorph carboxylic acid (BF-421-2)	334/107	98%	12		
					334/105	91%	8		
				Trifloxystrobin metab. CGA 321113	395/186	99%	10		
					395/145	93%	7		

Boscalid metab. M510F01, isoxaflutole metab. RPA202248, isoxaflutole metab. RPA203328 and dimoxystrobin metab. 505M09 were analyzed in the **ESI-negative** mode using 1,3-bis(4-



nitrophenyl)urea (BNPU) as internal standard. At the 0.01 mg/kg spiking level mean recovery rates were between 80-120% and RSDs  $\leq$  19 % for all compounds and both mass transitions with exception of RPA203328, that showed recovery rates between 66 and 78% and RSDs  $\leq$  10 %. At the 0.05 mg/kg spiking level mean recovery rates were within 80-120% range and RSDs  $\leq$  8 % in all cases with exception of RPA203328 that showed recovery rates between 66 and 80% and RSDs  $\leq$  8 %.

Some exemplary chromatograms are shown in Figure 1-Figure 8.



Table 6: Recovery data for Substances from various AO commodities using QuEChERS EN-15662 with C-18 cleanup (without PSA), n=5 (ESI-neg. mode using ABSciex API 4000 QTrap):

Matrix	Anal. Portion	Water added	Spiking level	Compound	Mass Transition [m/z]	Mean Recov. (n=5)	RSD %				
				Boscalid metab. M510F01	357/244	93%	5				
				Boscalid Metab. NISTOPOT	359/246	92%	10				
				Isoxaflutole metab. RPA202248	358/79	95%	3				
Muscle	5 g	5 mL	0.01 mg/kg	ISOXAIIUtole IIIetab. RPA202246	358/64	96%	5				
(bovine)			are a majoring	Isoxaflutole metab. RPA203328	267/159	66%	10				
				ISOXAIIUIOIE IIIEIAD. IXI AZUUSZU	267/223	66%	6				
				Dimoxystrobin metab. 505M09	355/106	96%	4				
				Billioxystrobili metab. 300wo3	355/266	97%	11				
				Boscalid metab. M510F01	357/244	92%	6				
				Boscand Metab. No for of	359/246	91%	3				
				Isoxaflutole metab. RPA202248	358/79	94%	2				
Muscle	5 g	5 mL	0.05 mg/kg	130xandiole metab. Ni A202240	358/64	95%	4				
(swine)				Isoxaflutole metab. RPA203328	267/159	67%	4				
				130xandiole metab. Ni A200320	267/223	68%	5				
				Dimoxystrobin metab. 505M09	355/106	100%	% 4 % 5				
				Dimoxystrobin metab. 300ivios	355/266	103%	5				
				Boscalid metab. M510F01	357/244	95%	6 11 6 6 6 3 6 2 6 4 6 4 6 5 7 6 6 6 5 6 5 6 7 8 3 8 6 5 8 8 6 3				
				Boscand Metab. NOTOFOT	359/246	91%	5				
Milk (cow's)				Isoxaflutole metab. RPA202248	358/79	94%	2				
	10 g	_	0.01 mg/kg	130 Autoto Metab. Ni 712022-10	358/64	94%	5				
	109		0.01 mg/kg	Isoxaflutole metab. RPA203328	267/159	78%	5				
				100 Autorio 1110 tabi. 111 712 000 20	267/223	77%	7				
				Dimoxystrobin metab. 505M09	355/106	100%	3				
				Billioxydilosiii iliotas. Goowlee	355/266	103%	6				
				Boscalid metab. M510F01	357/244	98%	5				
				Boosana motas. No for of	359/246	105%	8				
				Isoxaflutole metab. RPA202248	358/79	98%	3				
Milk	10 g	_	0.05 mg/kg	130Xallutole Metab. IXI A202240	358/64	95%	1				
(cow's)	10 9		0.00 mg/kg	Isoxaflutole metab. RPA203328	267/159	79%	6				
				100 Autorio Motas. Ni 7120020	267/223	80%	5				
				Dimoxystrobin metab. 505M09	355/106	100%	5				
				Dimensional metas. Cookies	355/266	104%	5				
				Boscalid metab. M510F01	357/244	119%	2				
				23344	359/246	103%	11				
			0.01 mg/kg	Isoxaflutole metab. RPA202248 Isoxaflutole metab. RPA203328	358/79	96%	4				
Liver	5 g	5 mL			358/64	94%	3				
(bovine)					267/159	77%	8				
				121.0.1010	267/223	77%	3				
				Dimoxystrobin metab. 505M09	355/106	109%	4				
				2lo.ky directin metab. edelwide	355/266	110%	18				



Matrix	Anal. Portion	Water added	Spiking level	Compound	Mass Transition [m/z]	Mean Recov. (n=5)	RSD %
				Boscalid metab. M510F01	357/244	115%	3
				Boscalia Metab. No for of	359/246	120%	8
				Isoxaflutole metab. RPA202248	358/79	98%	3
Liver	5 g	5 mL	0.05 mg/kg	isoxaliatole filetas. Ni 7/202240	358/64	98%	3
(bovine)				Isoxaflutole metab. RPA203328	267/159	72%	8
				isoxanatole metas. IX 7120022	267/223	74%	6
				Dimoxystrobin metab. 505M09	355/106	112%	6
				Billoxyoti obili iliotab. odolilo	355/266	108%	% 3 8 3 3 8 6
				Boscalid metab. M510F01	357/244	102%	19
				Deceand metab. We fet of	359/246	101%	12
				Isoxaflutole metab, RPA202248	358/79	100%	8
Kidney mix	5 g	5 mL	0.01 mg/kg	Tookanatole Metab. 14 7/2022 10	358/64	103%	4
(Swine+Bovine)				Isoxaflutole metab, RPA203328	267/159	72%	8
				isoxanatole metas. N. 7120022	267/223	72%	7
				Dimoxystrobin metab. 505M09	355/106	115%	4
				Billoxyoti obili iliotab. odolilo	355/266	110%	5
				Boscalid metab. M510F01	357/244	108%	6
				December Metal. Metal of	359/246	104%	6
				Isoxaflutole metab. RPA202248	358/79	97%	3
Kidney mix	5 g	5 mL	0.05 mg/kg	isoxanatole metab. Ni 7/202240	358/64	96%	2
(Swine+Bovine)				Isoxaflutole metab. RPA203328	267/159	69%	6
				issandio motas. N. 720020	267/223	66%	2
				Dimoxystrobin metab. 505M09	355/106	100%	3
				Zimeny direction in the day.	355/266	106%	5



#### Experiments to improve recovery rates of Isoxaflutole metabolite RPA203328

Using standard QuEChERS (with C18 cleanup) recoveries of the isoxaflutole metab. RPA203328 ranged between 66-80%. The low recoveries could be explained by the high polarity of this compound at the pH of the QuEChERS partitioning step of ~4 (logD -0.38 at pH4). It was therefore decided to conduct further validation experiments using the FA-QuEChERS procedure, which entails the use of acetonitrile containing 1% formic acid and the addition of 4g MgSO4 and 1 g NaCl for phase-separation (without citrate buffering salts). Here the partitioning is accomplished at a pH of ca 2.2, which proved beneficial for increasing the partitioning of this analyte to the acetonitrile phase. The recoveries of RPA203328 increased to 85-96% (see *Table 7*).

Table 7: Recovery rates for Isoxaflutole met. RPA203328 from various AO commodities using QuEChERS EN15662 and FA-QuEChERS, n=5 (ESI-neg. mode using Sciex API 4000 QTrap):

Matrix	Anal. Portion	Water added	Method	Spiking level	Mass Transition [m/z]	Mean Recov. (n=5)	RSD %
				0.01 mg/kg	267/159	77%	8
			QuEChERS EN15662	0.01 mg/kg	267/223	77%	3
Liver	5 g	5 mL	(citrate buffered)	0.05 ma/ka	267/159	72%	8
(bovine)	o g	OIIIL		0.05 mg/kg	267/223	74%	6
			FA-QuEChERS	RS 0.01	267/159	85%	6
			(with 1% FA)	mg/kg	267/223	94%	<b>6</b> <b>4</b> 8
				0.01 ma/ka	267/159	72%	8
			QuEChERS EN15662	0.01 mg/kg	267/223	72%	3 8 6 6 4
Kidney mix (Swine+Bovine)	5 g	5 mL	(citrate buffered)	0.05 mg/kg	267/159	69%	6
	o g	O IIIL	(0.11.01.01.01.01)	0.05 mg/kg	267/223	66%	2
			FA-QuEChERS	0.01	267/159	91%	10
			(with 1% FA)	mg/kg	267/223	96%	8



Experiments to localize the source of overestimated recovery rates for spiroxamine carboxylic acid and the fenpropidin metabolite CGA 289267 (in pre-experiments)

Interestingly first experiments showed overestimated recovery rates at low spiking levels for CGA289267 (fenpropidin metabolite) and spiroxamine carboxylic acid (see

Table 8). As these compounds entail strong basic groups with pKa values of 10 and 9.3 respectively, it was hypothesized that this effect might be due to a tendency of these compounds to interact with the glass surfaces via those basic groups within standard mixtures (in the absence of water). It was hypothesized the stronger recovery overestimations observed at the lower spiking levels would be due to proportionally higher losses of these compounds within the lowest concentrated standard solutions. Table 9 shows the results of an experiment confirming this hypothesis.

Table 8: Results of validation experiments of spiroxamine carboxylic acid and CGA 289267 (metabolite of fenpropidin); spiking level 0.01 mg/kg; n=5.

Notes: The working standard used to prepare the calibration solution (0.1  $\mu$ g/mL acetonitrile) was prepared by diluting the working standard that was used for spiking the analytical portions prior to extraction (1  $\mu$ g/mL acetonitrile). Both solutions

were prepared in glass vessels. Spiking volume was 100 μL in each case.

Matrix	Anal. Portion	Water added	Spiking level	Compound	Mass Trans. [m/z]	Mean Recov. (n=5)	RSD %
				Fenpropidin met. CGA 289267	304/107	210%	8
Muscle	5 g	5 mL	0.01 mg/kg	T empropidin met. CGA 209207	304/117	158%	10
(bovine)			3. 3	Spiroxamine carboxylic acid	328/144	156%	6
				Spiroxarriirie carboxylic acid	328/100	169%	10
				Fenpropidin met. CGA 289267	304/107	190%	10
Liver	5 g	5 mL	0.01 mg/kg	T empropidin met. CGA 209207	304/117	189%	10
(bovine)	9		0.01g/g	Spiroxamine carboxylic acid	328/144	153%	3
				Spiroxarriirie carboxylic acid	328/100	175%	10
				Fenpropidin met. CGA 289267	304/107	255%	4
Kidney mix 5 g	5 g	5 mL	0.01 mg/kg	renpropidin met. CGA 209207	304/117	277%	13
(Swine+Bovine)	- 3			Spiroxamine carboxylic acid	328/144	179%	5
				Spiroxariiile carboxylic acid	328/100	178%	8

Table 9: Check of 0.05 μg/mL mix used for calibration, due to too high recoveries of Spiroxamine carboxylic acid and CGA 289267 (metabolite of fenpropidin)

Concentration of ana- lytes in original mixture store in glass vessels (solvent: ACN)	Concentration of ana- lytes in freshly prepared dilution in PP vial (solvent: ACN)	Spriroxamine carboxylic acid	CGA 289267 (metabolite of fenpropidin)	Dimoxystrobin 505M09 (example for a non- affecetd compound)
0,05 μg/mL	0.025 μg/mL	41	30	98
0,25 μg/mL	0.025 μg/mL	85	77	93
1 μg/mL	0.025 μg/mL	100	100	100




Substance Recovery 1/5 0.01 ppm bovine muscle Wdf 1/5 0.05 ppm swine muscle 1.66 10000 3000 1500 8000 15000 6000 2000 1000 10000 4000 1000 5000 1.0 1.5 2.0 2.5 3.0 1.0 1.5 2.0 2.5 3.0 1.0 1.5 2.0 2.5 3.0 1.0 1.5 2.0 2.5 3.0 CGA 289267 (metabolite of CGA 289267 (metabolite of CGA 289267 (metabolite of CGA 289267 (metabolite of fenpropidin) 304/107 fenpropidin) 304/117 fenpropidin) 304/107 fenpropidin) 304/117 Recovery 1/5 0.01 ppm milk Recovery 1/5 0.05 ppm milk 8000 1.65 20000 -7000 3000 6000 15000 3e4 5000 4000 2000 10000 3000 2000 5000 1000 1.5 2.0 1.5 2.0 CGA 289267 (metabolite of CGA 289267 (metabolite of CGA 289267 (metabolite of CGA 289267 (metabolite of fenpropidin) 304/107 fenpropidin) 304/117 fenpropidin) 304/107 fenpropidin) 304/117 Fenpropidin Recovery 1/5 0.01 ppm bovine liver metabolite Recovery 1/5 0.05 ppm bovine liver CGA289267 15000 7000 4000 1500 6000 3000 5000 10000 1000 4000 2000 3000 5000 2000 1000 1.5 2.0 1.5 2.0 2.5 1.5 2.0 2.5 1.5 2.0 CGA 289267 (metabolite of CGA 289267 (metabolite of CGA 289267 (metabolite of CGA 289267 (metabolite of fenpropidin) 304/107 fenpropidin) 304/117 fenpropidin) 304/107 fenpropidin) 304/117 Recovery 1/5 0.01 ppm swine/bovine kidney Recovery 1/5 0.05 ppm swine/bovine kidney 4000 -8000 2500 15000 7000 3000 2000 6000 -5000 10000 1500 2000 4000 1000 3000 5000 1000 2000 1000 1.0 1.5 1 2.0 2.5 3.0 1.5 2.0 2.5 3.0 0.5 1.0 1.5 2.0 2.5 3.0 1.0 1.5 2.0 2.5 3.0 1.0 CGA 289267 (metabolite of CGA 289267 (metabolite of CGA 289267 (metabolite of CGA 289267 (metabolite of fenpropidin) 304/107 fenpropidin) 304/117 fenpropidin) 304/107 fenpropidin) 304/117

Figure 1: Exemplary chromatograms of Fenpropidin metabolite CGA 289267 in different matrices generated by API 4000



Figure 2: Exemplary chromatograms of Spiroxamine carboxylic acid in different matrices generated by API 4000





Substance Recovery 1/5 0.01 ppm bovine muscle Recovery 1/5 0.05 ppm swine muscle 8000 3.18 6000 7000 2.5e4 5000 6000 2.0e4 4000 5000 1.5e4 4000 3000 3000 1.0e4 2000 2000 5.0e3 1000 1000 0.0e0 3.0 3.5 4.0 4.5 3.0 3.5 4.0 4.5 3.0 3.5 4.0 4.5 2.0 2.5 3.0 3.5 4.0 4.5 2.5 2.0 2.5 2.5 Fenpropimorph Carboxylic Acid Fenpropimorph Carboxylic Acid Fenpropimorph Carboxylic Acid Fenpropimorph Carboxylic Acid 334/107 334/105 334/107 334/105 Recovery 1/5 0.01 ppm milk Recovery 1/5 0.05 ppm milk 15000 7e4 10000 10000 5e4 4e4 5000 5000 2e4 2.5 3.0 3.5 4.0 2.5 3.0 3.5 4.0 2.5 3.0 1 3.5 4.0 2.5 3.0 1 3.5 4.0 Fenpropimorph Carboxylic Acid Fenpropimorph Carboxylic Acid Fenpropimorph Carboxylic Acid Fenpropimorph Carboxylic Acid 334/107 334/105 334/107 334/105 Fenpropimorph Recovery 1/5 0.01 ppm bovine liver Recovery 1/5 0.05 ppm bovine liver carboxylic acid (BF-421-2) 3.16 3.0e4 8000 2.5e4 5000 6000 2.0e4 4000 1.5e4 3000 4000 1.0e4 2000 2000 1000 5.0e3 2.5 3.0 4.0 2.5 3.0 3.0 3.0 Fenpropimorph Carboxylic Acid Fenpropimorph Carboxylic Acid Fenpropimorph Carboxylic Acid Fenpropimorph Carboxylic Acid 334/107 334/105 334/107 334/105 Recovery 1/5 0.01 ppm swine/bovine kidney Recovery 1/5 0.05 ppm swine/bovine kidney 9000 3.0e4 8000 6000 7000 2.5e4 5000 6000 2.0e4 4000 5000 1.5e4 4000 3000 3000 1.0e4 2000 2000 1000 5.0e3 2.0 2.5 3.0 3.5 4.0 4.5 2.0 2.5 3.0 3.5 4.0 4.5 2.0 2.5 3.0 3.5 4.0 4.5 2.0 2.5 3.0 3.5 4.0 4.5 Fenpropimorph Carboxylic Acid Fenpropimorph Carboxylic Acid Fenpropimorph Carboxylic Acid Fenpropimorph Carboxylic Acid 334/107 334/105 334/107 334/105

Figure 3: Exemplary chromatograms of Fenpropimorph carboxylic acid (BF-421-2) in different matrices generated by API 4000



Substance Recovery 1/5 0.01 ppm bovine muscle Recovery 1/5 0.05 ppm swine muscle 4000 20000 1500 -3000 10000 15000 2000 1000 10000 5000 1000 5000 2.5 3.0 3.5 4.0 4.5 2.5 3.0 3.5 4.0 4.5 2.5 3.0 3.5 4.0 4.5 2.5 3.0 3.5 4.0 4.5 Trifloxystrobin acid 395/186 Trifloxystrobin acid 395/145 Trifloxystrobin acid 395/186 Trifloxystrobin acid 395/145 Area: 1.786e4 Area: 9.136e3 Area: 9.875e4 Area: 6.131e4 Recovery 1/5 0.05 ppm milk Recovery 1/5 0.01 ppm milk 3.44 8000 25000 7000 5000 -6000 20000 4000 5000 15000 3000 4000 3000 10000 2000 2000 5000 1000 1000 3.0 3.5 4.0 3.0 3.5 3.0 2.5 3.0 3.5 4.0 Trifloxystrobin acid 395/186 Trifloxystrobin acid 395/145 Trifloxystrobin acid 395/186 Trifloxystrobin acid 395/145 Area: 2.505e4 Area: 3.643e4 Area: 1.777e5 Area: 1.141e5 Trifloxystrobin Recovery 1/5 0.01 ppm bovine liver Recovery 1/5 0.05 ppm bovine liver met. CGA 321113 5000 2500 4000 15000 2000 10000 3000 1500 10000 2000 1000 5000 5000 1000 500 2.5 3.0 3.5 4.0 2.5 3.0 3.5 2.5 3.0 3.5 4.0 3.0 3.5 4.0 Trifloxystrobin acid 395/186 Trifloxystrobin acid 395/145 Trifloxystrobin acid 395/186 Trifloxystrobin acid 395/145 Area: 2.126e4 Area: 1.201e4 Area: 9.722e4 Area: 6.407e4 Recovery 1/5 0.01 ppm swine/bovine kidney Recovery 1/5 0.05 ppm swine/bovine kidney 3000 2000 1000 -2500 1500 800 1500 2000 600 1000 1500 1000 400 1000 500 500 500 2.5 3.0 3.5 4.0 4.5 2.5 3.0 3.5 4.0 4.5 2.5 3.0 3.5 4.0 4.5 2.5 3.0 3.5 4.0 4.5 Trifloxystrobin acid 395/186 Trifloxystrobin acid 395/145 Trifloxystrobin acid 395/186 Trifloxystrobin acid 395/145 Area: 9.605e3 Area: 5.481e3 Area: 1.312e4 Area: 8.106e3

Figure 4: Exemplary chromatograms of Trifloxystrobin met. CGA 321113 in different matrices generated by API 4000



Figure 5: Exemplary chromatograms of Boscalid metabolite M510F01 in different matrices generated by API 4000 Substance Recovery 1/5 0.01 ppm bovine muscle Recovery 1/5 0.05 ppm swine muscle 4000 1200 10000 3000 1000 8000 3000 800 2000 6000 2000 4000 400 1000 2000 1.5 2.0 2.5 3.0 0.5 1.0 1.5 2.0 2.5 1.0 1.5 12.0 2.5 3.0 1.0 1.5 2.0 2.5 3.0 M510F01 (Metab. Boscalid) 357/244 M510F01 (Metab. Boscalid) 359/246 M510F01 (Metab. Boscalid) 357/244 M510F01 (Metab. Boscalid) 359/246 Area: 1.537e4 Area: 5.700e3 Area: 4.050e4 Area: 1.409e4 Recovery 1/5 0.01 ppm milk Recovery 1/5 0.05 ppm milk 9000 -1.87 8000 2000 7000 6000 10000 1500 5000 2e4 4000 1000 3000 5000 2000 -500 1000 -1.5 2.0 1.5 2.0 1.5 2.0 2.5 1.5 2.0 M510F01 (Metab. Boscalid) 359/246 M510F01 (Metab. Boscalid) 359/246 M510F01 (Metab. Boscalid) 357/244 M510F01 (Metab. Boscalid) 357/244 Area: 1.389e5 Area: 3.247e4 Area: 1.026e4 Area: 5.246e4 Boscalid Recovery 1/5 0.01 ppm bovine liver Recovery 1/5 0.05 ppm bovine liver metabolite M510F01 2500 4000 2000 600 10000 3000 1500 400 2000 300 1000 5000 200 1000 500 1.5 2.0 2.0 1.5 2.0 1.5 2.0 1.5 M510F01 (Metab. Boscalid) 357/244 M510F01 (Metab. Boscalid) 359/246 M510F01 (Metab. Boscalid) 357/244 M510F01 (Metab. Boscalid) 359/246 Area: 1.011e4 Area: 3.619e3 Area: 5.310e4 Area: 1.691e4 Recovery 1/5 0.01 ppm swine/bovine kidney Recovery 1/5 0.05 ppm swine/bovine kidney 4000 -20000 6000 5000 3000 1000 15000 4000 2000 10000 3000 500 2000 1000 5000 1000 1.0 1.5 2.0 2.5 3.0 1.5 2.0 2.5 3.0 1.5 **1**2.0 2.5 3.0 1.5 2.0 2.5 3.0 M510F01 (Metab. Boscalid) 359/246 M510F01 (Metab. Boscalid) 359/246 M510F01 (Metab. Boscalid) 357/244 M510F01 (Metab. Boscalid) 357/244

Area: 5.502e3

Area: 1.561e4

Area: 2.553e4

Area: 7.822e4




Substance Recovery 1/5 0.01 ppm bovine muscle Recovery 1/5 0.05 ppm swine muscle 15000 4 6000 -1.2e5 5000 -1.0e5 5e4 10000 4000 8.0e4 3000 6.0e4 5000 2000 4.0e4 1000 2.0e4 0.0e0 1.5 2.0 2.5 3.0 1.0 1.9 2.0 2.5 1.0 1.9 2.0 1.0 1.0 1.5 2.0 2.5 3.0 Isoxaflutole, RPA 202248 358/79 Isoxaflutole, RPA 202248 358/64 Isoxaflutole, RPA 202248 358/79 Isoxaflutole.RPA 202248 358/64 Area: 8.542e4 Area: 3.894e4 Area: 5.524e5 Area: 2.883e5 Recovery 1/5 0.05 ppm milk Recovery 1/5 0.01 ppm milk 1.54 1.61 25000 1.2e5 2.0e5 10000 1.0e5 20000 8000 8.0e4 15000 6000 6.0e4 10000 4000 4.0e4 5.0e4 5000 2000 2.0e4 1.9 2.0 1.5 2.0 2.5 1.5 2.0 1.0 1.0 Isoxaflutole, RPA 202248 358/79 Isoxaflutole, RPA 202248 358/64 Isoxaflutole, RPA 202248 358/79 Isoxaflutole, RPA 202248 358/64 Area: 1.597e5 Area: 7.269e4 Area: 1.093e6 Area: 5.684e5 Isoxaflutole Recovery 1/5 0.01 ppm bovine liver met. Recovery 1/5 0.05 ppm bovine liver RPA202248 15000 3.0e4 6000 5e4 2.5e4 5000 10000 4e4 2.0e4 4000 3e4 1.5e4 3000 5000 2000 2e4 1.0e4 1e4 5.0e3 1000 0.0e0 1.9 2.0 1.9 2.0 2.5 1.9 2.0 2.5 Isoxaflutole, RPA 202248 358/79 Isoxaflutole, RPA 202248 358/64 Isoxaflutole, RPA 202248 358/79 Isoxaflutole, RPA 202248 358/64 Area: 8.668e4 Area: 3.756e4 Area: 4.001e5 Area: 1.848e5 Recovery 1/5 0.01 ppm swine/bovine kidney Recovery 1/5 0.05 ppm swine/bovine kidney 3.0e4 6e4 5000 2.5e4 10000 4000 2.0e4 3000 1.5e4 3e4 5000 2000 1.0e4 2e4 1000 5.0e3 0.5 1.0 1.9 2.0 2.5 0.5 1.0 1.9 2.0 2.5 1.0 1.9 2.0 2.5 0.5 1.0 1.9 2.0 2.5 Isoxaflutole, RPA 202248 358/79 Isoxaflutole, RPA 202248 358/64 Isoxaflutole, RPA 202248 358/79 Isoxaflutole, RPA 202248 358/64 Area: 7.766e4 Area: 3.562e4 Area: 4.110e5 Area: 1.924e5

Figure 6: Exemplary chromatograms of Isoxaflutole met. RPA202248 in different matrices generated by API 4000



Figure 7: Exemplary chromatograms of Isoxaflutole met. RPA203328 in different matrices generated by API 4000





Substance Recovery 1/5 0.01 ppm bovine muscle Recovery 1/5 0.05 ppm swine muscle 7000 14000 5000 -6000 12000 12000 4000 5000 10000 10000 4000 2000 8000 3000 3000 6000 6000 2000 2000 4000 4000 1000 1000 2000 2000 1.5 2.0 2.5 3.0 1.5 2.0 2.5 3.0 1.0 1.5 2.0 2.5 3.0 1.5 2.0 2.5 3.0 Dimoxystrobin 505M09 355/106 Dimoxystrobin 505M09 355/266 Dimoxystrobin 505M09 355/106 Dimoxystrobin 505M09 355/266 Area: 2.469e4 Area: 2.008e4 Area: 5.852e4 Area: 4.903e4 Recovery 1/5 0.01 ppm milk Recovery 1/5 0.05 ppm milk 12000 1.95 1.95 10000 10000 8000 8000 6000 2e4 6000 4000 4000 2000 2000 2.0 1.5 2.5 1.5 2.0 2.5 1.5 2.0 Time, min Dimoxystrobin 505M09 355/106 Dimoxystrobin 505M09 355/266 Dimoxystrobin 505M09 355/106 Dimoxystrobin 505M09 355/266 Area: 1.376e5 Area: 4.604e4 Area: 3.922e4 Area: 1.580e5 Dimoxystrobin Recovery 1/5 0.01 ppm bovine liver Recovery 1/5 0.05 ppm bovine liver met. 505M09 6000 20000 25000 5000 20000 4000 -15000 4000 3000 15000 3000 10000 10000 2000 2000 1000 5000 1000 1.5 2.0 2.5 1.5 2.0 2.5 3.0 1.5 2.0 2.5 1.5 2.0 2.5 Dimoxystrobin 505M09 355/266 Dimoxystrobin 505M09 355/106 Dimoxystrobin 505M09 355/266 Dimoxystrobin 505M09 355/106 Area: 2.305e4 Area: 1.953e4 Area: 1.020e5 Area: 8.120e4 Recovery 1/5 0.01 ppm swine/bovine kidney Recovery 1/5 0.05 ppm swine/bovine kidney 6000 25000 5000 2.5e4 5000 20000 4000 2.0e4 4000 15000 3000 1.5e4 3000 2000 10000 1.0e4 2000 1000 5.0e3 5000 1000 1.0 1.5 2.0 2.5 3.0 1.5 2.0 2.5 3.0 1.0 1.5 2.0 2.5 3.0 1.5 2.0 2.5 3.0 Dimoxystrobin 505M09 355/106 Dimoxystrobin 505M09 355/266 Dimoxystrobin 505M09 355/106 Dimoxystrobin 505M09 355/266 Area: 2.305e4 Area: 1.953e4 Area: 1.110e5 Area: 1.025e5

Figure 8: Exemplary chromatograms of Dimoxystrobin met. 505M09 in different matrices generated by API 4000



#### **Discussion and conclusions:**

Metabolites of several pesticides relevant to food of animal origin were successfully validated using QuEChERS or variations of it. These analytes were the following: boscalid metabolite M510F01, dimoxystrobin metabolite 505M09, fenpropidin metabolite CGA289267, fenpropimorph metabolite BF421-2, isoxaflutole metabolite RPA 203328 and RPA 203348, spiroxamine carboxylic acid, and trifloxystrobin metabolite CGA 321113.

Lacking samples with incurred residues the validation of the boscalid metabolite M510F01 focused only on the parent compound and not the conjugates, which are also entailed in the residue definition.

The isoxaflutole metabolite RPA 203348 showed low recoveries using citrate buffered QuEChERS. Successfully validation was accomplished using the FA-QuEChERS (use of acetonitrile acidified with 1% formic acid).

Spiroxamine carboxylic acid and the fenpropidin metabolite CGA 289267 showed a strong tendency to interact with glass surface. It is thus indicated to use PP vials for these compounds.

#### **History**

Action	When	Document Version
Initial Experiments	Oct - Dec 2017	
Further Experiments	Jan – March 2018	
Observation document placed on-line	March 2018	V1